These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 31004621

  • 1. Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity.
    Leemans A, Boeren M, Van der Gucht W, Martinet W, Caljon G, Maes L, Cos P, Delputte P.
    Virus Res; 2019 Jun; 266():58-68. PubMed ID: 31004621
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B, Matsuoka Y, Le Nouën C, Liu X, Herbert R, Swerczek J, Santos C, Paneru M, Collins PL, Buchholz UJ, Munir S.
    J Virol; 2020 Dec 22; 95(2):. PubMed ID: 33115876
    [Abstract] [Full Text] [Related]

  • 6. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B, Kabatova B, Kabat J, Dorward DW, Liu X, Surman S, Liu X, Moseman AP, Buchholz UJ, Collins PL, Munir S.
    J Virol; 2019 Apr 01; 93(7):. PubMed ID: 30651356
    [Abstract] [Full Text] [Related]

  • 7. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2015 Sep 01; 89(18):9499-510. PubMed ID: 26157122
    [Abstract] [Full Text] [Related]

  • 8. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.
    J Virol; 2017 May 15; 91(10):. PubMed ID: 28250126
    [Abstract] [Full Text] [Related]

  • 9. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.
    J Virol; 2017 Jun 01; 91(11):. PubMed ID: 28298602
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.
    J Virol; 2017 Nov 15; 91(22):. PubMed ID: 28835504
    [Abstract] [Full Text] [Related]

  • 13. N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus.
    Zimmer G, Trotz I, Herrler G.
    J Virol; 2001 May 15; 75(10):4744-51. PubMed ID: 11312346
    [Abstract] [Full Text] [Related]

  • 14. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JCG, Moin SM, Graham BS, Piedra PA, Moore ML.
    J Virol; 2016 Aug 15; 90(16):7508-7518. PubMed ID: 27279612
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N, Amaro-Carambot E, Liang B, Surman S, Lingemann M, Yang L, Collins PL, Munir S.
    J Virol; 2015 Oct 15; 89(20):10319-32. PubMed ID: 26223633
    [Abstract] [Full Text] [Related]

  • 17. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L, Durr E, Galli JD, Cosmi S, Cejas PJ, Luo B, Touch S, Parmet P, Fridman A, Espeseth AS, Bett AJ.
    Vaccine; 2018 Dec 18; 36(52):8119-8130. PubMed ID: 30340881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. trans-Complementation allows recovery of human respiratory syncytial viruses that are infectious but deficient in cell-to-cell transmission.
    Oomens AG, Wertz GW.
    J Virol; 2004 Sep 18; 78(17):9064-72. PubMed ID: 15308702
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.